The impact of chromosomal microarray on clinical management: a retrospective analysis

@article{Henderson2014TheIO,
  title={The impact of chromosomal microarray on clinical management: a retrospective analysis},
  author={Lindsay B. Henderson and Carolyn D Applegate and Elizabeth Squibb Wohler and Molly B. Sheridan and Julie E Hoover-Fong and Denise A. S. Batista},
  journal={Genetics in Medicine},
  year={2014},
  volume={16},
  pages={657-664}
}
Purpose:Chromosomal microarray has been widely adopted as the first-tier clinical test for individuals with multiple congenital anomalies, developmental delay, intellectual disability, and autism spectrum disorders. Although chromosomal microarray has been extensively shown to provide a higher diagnostic yield than conventional cytogenetic methods, some health insurers refuse to provide coverage for this test, claiming that it is experimental and does not affect patients’ clinical management… CONTINUE READING